Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

56.00USD
19 Oct 2017
Change (% chg)

$0.23 (+0.41%)
Prev Close
$55.77
Open
$55.90
Day's High
$56.18
Day's Low
$55.41
Volume
4,865,319
Avg. Vol
5,724,957
52-wk High
$56.60
52-wk Low
$37.38

Chart for

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.57
Market Cap(Mil.): $95,559.38
Shares Outstanding(Mil.): 1,737.44
Dividend: 0.26
Yield (%): 1.93

Financials

  Industry Sector
P/E (TTM): -- 30.44 16.24
EPS (TTM): -- -- --
ROI: -- 14.17 10.90
ROE: -- 15.52 14.09

BRIEF-Abbott CFO says Alere is expected to contribute around $475 mln to reported sales this year

* Abbott CFO says Alere, is expected to contribute around $475 million to reported sales, and forecast a neutral impact on adjusted earnings per share this year - Conf Call

Oct 18 2017

Abbott's recent deals, medical device pipeline to fuel growth

Abbott Laboratories' quarterly results beat estimates and the company raised the top end of its full-year earnings forecast range on Wednesday, as a string of recent deals and medical device approvals help spur growth in its largest unit.

Oct 18 2017

UPDATE 3-Abbott's recent deals, medical device pipeline to fuel growth

* Shares up 2.8 pct to record high (Adds conference call details, updates shares)

Oct 18 2017

BRIEF-Abbott Q3 adjusted EPS $0.66 from continuing operations

* Sees FY 2017 gaap earnings per share $0.97 to $0.99 from continuing operations

Oct 18 2017

Abbott Labs posts quarterly profit vs. year-ago loss

Oct 18 Diversified healthcare company Abbott Laboratories on Wednesday reported a quarterly profit compared with a loss in the year-ago quarter, helped by strong sales in its medical devices and generics businesses.

Oct 18 2017

AbbVie, Abbott duck Depakote off-label marketing case on appeal

A federal appeals court on Thursday upheld the dismissal of a class action lawsuit accusing AbbVie Inc and Abbott Laboratories of violating federal racketeering laws by promoting the drug Depakote for off-label uses.

Oct 12 2017

BRIEF-Abbott completes cash tender offer for Series B Convertible Perpetual Preferred Stock of Alere Inc

* Abbott completes cash tender offer for Series B Convertible Perpetual Preferred Stock of Alere Inc. Source text for Eikon: Further company coverage:

Oct 04 2017

BRIEF-Abbott extends previous cash tender offer for outstanding Series B shares of Alere Inc

* Abbott announces extension of cash tender offer for all outstanding shares of Series B convertible perpetual preferred stock of Alere Inc.

Oct 02 2017

BRIEF-Abbott acquisition of Alere set to close on October 3, 2017

* Abbott acquisition of Alere set to close on Tuesday, October 3, 2017

Sep 29 2017

Abbott wins U.S. antitrust approval to buy Alere with conditions

WASHINGTON Abbott Laboratories has won U.S. antitrust approval to buy Alere Inc on condition that it sell two point-of-care medical testing businesses, the Federal Trade Commission said on Thursday.

Sep 28 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.04 +1.36
Pfizer Inc. (PFE.N) $36.24 +0.41
Novartis AG (NOVN.S) CHF84.35 -0.30
Merck & Co., Inc. (MRK.N) $63.75 +0.24
Sanofi SA (SASY.PA) €84.26 --
AstraZeneca plc (AZN.L) 5,175.00 -1.00
GlaxoSmithKline plc (GSK.L) 1,536.00 +2.50
Eli Lilly and Co (LLY.N) $86.36 +0.63
Amgen, Inc. (AMGN.OQ) $184.12 -2.16
Boston Scientific Corporation (BSX.N) $29.57 +0.05

Earnings vs. Estimates